<DOC>
	<DOCNO>NCT02431221</DOCNO>
	<brief_summary>A Study Efficacy , Safety , Tolerability Perhexiline maleate Subjects Hypertrophic Cardiomyopathy Moderate-To-Severe Heart Failure</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Perhexiline Subjects With Hypertrophic Cardiomyopathy Heart Failure</brief_title>
	<detailed_description>This study international , multi-center , randomize , double-blind , placebo control clinical trial effect perhexiline maleate rank-ordered , hierarchical variable consist outcome functional measure 350 subject hypertrophic cardiomyopathy symptom moderate severe congestive heart failure . The study design four part : 1 ) open-label run-in period 2 week , 2 ) A blind , randomized phase variable duration ( anticipated 6 month 18 month depend enrollment rate ) , 3 ) open label period 3 month , 4 ) randomize withdrawal period 3 month . Subjects experience adverse outcome ( death resuscitate ventricular arrhythmia , stroke , need surgical intervention , cardiovascular hospitalization , occurrence atrial fibrillation , study dropout ) undergo cardiopulmonary exercise test order determine change baseline maximum oxygen consumption .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Perhexiline</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>General Criteria 1 . Adult , least 18 year age 2 . Able willing give write informed consent Cardiomyopathyrelated Criteria 3 . Hypertrophic cardiomyopathy ( HCM ) moderatetosevere heart failure define meeting follow criterion : 1 . HCM meeting 2011 ACCF/AHA Criteria Diagnosis Hypertrophic Cardiomyopathy ( Gersh et al . 2011 ) 2 . Left ventricular hypertrophy ( LVH ) maximum LV wall thickness &gt; 15 mm echocardiography cardiac magnetic resonance image without alternative explanation 3 . Left ventricular ejection fraction ( LVEF ) &gt; 40 % 4 . Able perform exercise test unable exceed 75 % predict ageadjusted maximum level ( determined METs achieve exercise testingâ€”eligibility base VO2max ) 4 . Normal sinus rhythm Screening Baseline ( atrial fibrillation pattern acceptable subject know chronic atrial fibrillation ) 5 . If taking medication treatment HCM ( include betablockers , calcium channel blocker , disopyramide , diuretic ) , medication take stable dose least 60 day prior enrollment continue dose throughout study General Criteria 1 . Pregnant woman , woman intend become pregnant , woman practice contraception , either pharmacologically barrier method 2 . Lactating woman 3 . CYP2D6 Poor Metabolizer ( PM ) status , base genotype know prior Screening , predict genotype assess Screening CYP2D6 Poor Metabolizer ( PM ) status define functional CYP2D6 allele genotyping ( exclusively allele combination *3 , *4 , *5 , *6 , *7 , *8 , *12 , *14 ) . 4 . Any subject regularly take medication know strong inhibitor CYP2D6 ( bupropion , fluoxetine , paroxetine , quinidine , ritonavir ) 5 . Any concomitant disease , condition , treatment could interfere conduct study , would , opinion investigator sponsor , pose unacceptable risk subject and/or interfere interpretation study data , include limited : 1 . History know toxic inflammatory peripheral neuropathy , mononeuritis multiplex , acute chronic inflammatory demyelinate polyneuropathy ( AIDP CIDP ) , axonal sensorimotor neuropathy , drugrelated neuropathy neuritis , diabetic neuropathy ( history compression neuropathy , carpal tunnel syndrome , acceptable ) 2 . Poorly control diabetes mellitus ( e.g. , HbA1c &gt; 8.5 % ) 3 . Clinically severe chronic obstructive pulmonary disease ( i.e . COPD require home oxygen history IV oral steroid use ) 4 . History known chronic liver disease include cirrhosis cause , chronic hepatitis B hepatitis C 5 . History porphyria 6 . History recurrent hypoglycemia 7 . Active infection require antibiotic 8 . Life expectancy le 2 year 9 . Evidence active suspect cancer history malignancy , except skin squamous cell basal cell carcinoma require systemic therapy consider cure 10 . History substance abuse , include alcohol illicit drug within past 12 month 11 . Abnormal safety study clinical significance Screening : i. Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , lactate dehydrogenase &gt; 1.5X upper limit normal ( ULN ) ii . Glucose &lt; 70 mg/dL iii . Prolonged QTc ( &gt; 450 msec ) l. Known hypersensitivity perhexiline maleate 6 . Unable unwilling comply protocol 7 . Enrolled another therapeutic trial hypertrophic cardiomyopathy Cardiomyopathyrelated Exclusion Criteria 8 . Asymptomatic subject subject whose symptom control medication 9 . Resting LVOT gradient &gt; 50 mmHg know exerciseinduced LVOT gradient &gt; 80 mmHg 10 . Absence implant , operational ICD history frequent nonsustained ventricular tachycardia , first degree relative sudden cardiac death ICD implant 11 . Known coronary artery disease ( &gt; 50 % arterial luminal narrowing major epicardial vessel ) 12 . History cardiac transplantation 13 . Cardiac surgery septal reduction surgery plan occur within past 6 month 14 . HCM believe cause infiltrative disorder , glycogen storage disorder , hypertensive heart disease ( include genotypic phenotypic evidence Fabry 's Disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>perhexiline</keyword>
	<keyword>HCM</keyword>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
	<keyword>CPEX</keyword>
</DOC>